CAR T-cell Resistance to Oncogenic Transformation.
Marco RuellaCarl H JunePublished in: Blood cancer discovery (2024)
In this commentary, we discuss the investigation into reports of T-cell malignancies following chimeric antigen receptor T-cell therapy. We argue that although these cases should be thoroughly examined, current data suggest that such risks with autologous chimeric antigen receptor T cells are remarkably low compared with other cancer treatments. We also emphasize the importance of continued research, transparent reporting, and participation in postauthorization safety studies.
Keyphrases
- cell therapy
- adverse drug
- stem cells
- papillary thyroid
- mesenchymal stem cells
- electronic health record
- squamous cell
- big data
- transcription factor
- human health
- case control
- squamous cell carcinoma
- machine learning
- childhood cancer
- bone marrow
- young adults
- artificial intelligence
- deep learning
- climate change
- light emitting